The objective of the present study was to formulate sustained-release matrix tablets of Lornoxicam, for treatment of pain relief. The matrix tablets were prepared by wet granulation method using hydroxyl propyl methylcellulose and Eudragit in various concentrations. The powder showed satisfactory flow properties and compressibility. All the formulations showed acceptable pharmacopoeial standards. The result of formulation F6. Model fitting analysis for formulation F6 fitted in the zero order model and Korsemeyer- Peppas model. The ‘n’ values obtained from the Peppas-Korsemeyer equation suggested that drug release was non-Fickian diffusion mechanism. Successful formulation was found stable after evaluation for physicochemical parameters when kept for 90 days at room temperature, 400c and 2-8 0 c. It concluded that sustained release matrix tablets of Lornoxicam containing 25% of HPMC K4M and eudragit provide a better option for the Sustained release of the drug.